VPI 2690B

Drug Profile

VPI 2690B

Alternative Names: VPI-2690B

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of North Carolina
  • Developer Vascular Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists; Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies

Most Recent Events

  • 01 Mar 2017 Vascular Pharmaceuticals completes a phase II trial in Diabetic nephropathies in USA and Puerto Rico (NCT02251067)
  • 09 Dec 2016 VPI 2690B is still in phase II trials for Diabetic nephropathies in USA (NCT02251067)
  • 01 Sep 2014 Phase-II clinical trials in Diabetic nephropathies in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top